# Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

> **NCT00559962** · PHASE2 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 260 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** AEGR-733
- **DRUG:** placebo
- **DRUG:** AEGR-733
- **DRUG:** AEGR-733
- **DRUG:** AEGR-733
- **DRUG:** AEGR-733 and atorvastatin
- **DRUG:** AEGR-733 and fenofibrate
- **DRUG:** AEGR-733 and ezetimibe

## Key facts

- **NCT ID:** NCT00559962
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-11
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2018-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559962, "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00559962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*